

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme.
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21 NOV 13 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22 NOV 20 CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24 NOV 20 CA/CAplus patent kind codes will be updated
NEWS 25 DEC 01 CAS REGISTRY updated with new ambiguity codes
NEWS 26 DEC 11 CAS REGISTRY chemical nomenclature enhanced

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* STN Columbus *

FILE 'HOME' ENTERED AT 08:46:41 ON 14 DEC 2006

FILE 'REGISTRY' ENTERED AT 08:46:48 ON 14 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 DEC 2006 HIGHEST RN 915360-23-5
DICTIONARY FILE UPDATES: 13 DEC 2006 HIGHEST RN 915360-23-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> Uploading C:\Program Files\Stnexp\Queries\10798766\Struc 1.str




Page 3

```
chain nodes :  
7  
ring nodes :  
1 2 3 4 5 6 8 9 10 11 12  
chain bonds :  
4-7 6-8  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12  
exact/norm bonds :  
4-7 8-9 8-12 9-10 10-11 11-12  
exact bonds :  
6-8  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
  
Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom
```

L1 STRUCTURE UPLOADED

```
=> d  
L1 HAS NO ANSWERS  
L1 STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> l1  
SAMPLE SEARCH INITIATED 08:47:00 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 371 TO ITERATE
```

```
100.0% PROCESSED 371 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01 50 ANSWERS
```


10798766.trn

Page 4

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6265 TO 8575
PROJECTED ANSWERS: 656 TO 1544

L2 50 SEA SSS SAM L1

=> Uploading C:\Program Files\Stnexp\Queries\10798766\Struc 2.str



chain nodes :

7 13 14

ring nodes :

1 2 3 4 5 6 8 9 10 11 12

chain bonds :

4-7 6-8 10-13 13-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12

exact/norm bonds :

4-7 8-9 8-12 9-10 10-11 11-12 13-14,

exact bonds :

6-8 10-13

normalized bonds :


1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> 13
SAMPLE SEARCH INITIATED 08:48:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS 17 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 173 TO 747
PROJECTED ANSWERS: 93 TO 587
```

L4 17 SEA SSS SAM L3

```
=> 13 full
FULL SEARCH INITIATED 08:48:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 502 TO ITERATE

100.0% PROCESSED 502 ITERATIONS 369 ANSWERS
SEARCH TIME: 00.00.01
```

L5 369 SEA SSS FUL L3

```
=> file medline caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
                           ENTRY SESSION
FULL ESTIMATED COST      167.82    168.03
```

FILE 'MEDLINE' ENTERED AT 08:48:40 ON 14 DEC 2006

FILE 'CAPLUS' ENTERED AT 08:48:40 ON 14 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> 15

10798766.trn

Page 6

L6 9 L5

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7 9 DUP REM L6 (0 DUPLICATES REMOVED)

=> d ibib abs hitstr 1-9

BEST AVAILABLE COPY

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:656035 CAPLUS
 DOCUMENT NUMBER: 145:124595
 TITLE: Preparation of pyrrolylpyrimidines as selective inhibitors of erk protein kinase and uses thereof
 INVENTOR(S): Aronov, Alex; Hale, Michael R.; Maltais, Francois; Martinez-Botella, Gabriel; Straub, Judith; Tang, Qing
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2006071644 | A1 | 20060706 | WO 2005-US46177 | 20051220 |
| WO 2006071644 | C1 | 20060824 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| US 2006160807 | A1 | 20060720 | US 2005-312618 | 20051220 |
| PRIORITY APPLN. INFO.: | | | US 2004-638502P | P 20041223 |

OTHER SOURCE(S): MARPAT 145:124595
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [X = Ph or 5-6-membered heterocycle; RI = CN, halo, OH, etc.; R2 = H, halo, CO2H, CN, etc.; R3 and R4 independently = o xo, NO2, F, Cl, alkoxy, etc.; n = 0-4; p = 0-2], and their pharmaceutically acceptable salts, are prepared and disclosed as ERK2 inhibitors. Thus, e.g., II was prepared in a multi-step synthesis from 2,2,2-trichloro-1-(1H-pyrrol-2-yl)ethanone. I were evaluated for inhibition of ERK2, e.g., II was determined to possess a Ki value of $\leq 0.1 \mu\text{M}$. These compds., and pharmaceutically acceptable compns. thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferate disorders such as cancer.

IT 449732-19-8P 896720-20-OP 896720-21-1P

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 896720-22-2P 896720-23-3P 896720-24-4P
 896720-25-5P 896720-26-6P 896720-27-7P
 896720-28-8P 896720-29-9P 896720-30-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of pyrrolylpyrimidines as selective inhibitors of erk protein kinase and uses thereof)

RN 449732-19-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-(trifluoromethyl)phenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 896720-20-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(2-chloro-4-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 896720-21-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(2-chloro-4-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 896720-22-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,4-dichlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 896720-23-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(2-chloro-4-nitrophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 896720-24-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(2-chloro-5-hydroxyphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

BEST AVAILABLE COPY

Page 8

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 896720-25-5 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,3-dichlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 896720-26-6 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 896720-27-7 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,6-dichlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 896720-28-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chloro-6-methylphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 896720-29-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 896720-30-2 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1259560 CAPLUS
 DOCUMENT NUMBER: 144:7094
 TITLE: Prodrugs of pyrrolylpyrimidine ERK protein kinase inhibitors
 INVENTOR(S): Martinez-Bottella, Gabriel; Hale, Michael R.; Maltais, Francois; Tang, Qing; Straub, Judith
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA
 SOURCE: PCT Int. Appl., 49 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|--|-----------------|------------|
| WO 2005113546 | A1 | 20051201 | WO 2005-US16801 | 20050513 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | |
| US 2006058318 | A1 | 20060316 | US 2005-129114 | 20050513 |
| PRIORITY APPLN. INFO.: | | | US 2004-571283P | P 20040514 |


OTHER SOURCE(S): MARPAT 144:7094

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrrolylpyrimidine compds. II (R1 = H, TCO2R2, TCO(CH2)nCO2R2, TCO(CH2)nCONR32, TCO(CH2)nCHR2NR32, TPO2R22, provided that at least one R1 is not H; T = a valence bond or CR420; R2 = R3 = H, (un)substituted Cl-6 aliphatic group or (un)substituted 5-6 membered saturated, partially or fully unsatd. ring having 0-4 heteroatoms selected from N, O, S, or R3 = COR2, CO2R2, SO2R2, OR2, etc.; N = O-6; O = Cl-10 alkylidene wherein 0-4 methylene units of O replaced by O, NR4, S, SO, SO2, CO; R4 = H, or (un)substituted Cl-6 aliphatic group) were prepared as prodrugs of ERK protein kinase inhibitors for the treatment of various diseases, conditions, or disorders. Thus, parent compound 4-(2-1-(hydroxymethylpropylamino)-5-Me pyrimidin-4-yl)-1H-pyrrole-2-carboxylic

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



PAGE 1-A

NHMe

● 3 HCl

IT 869962-37-8P 869962-38-9P 869962-39-0P
 869962-40-3P 869962-41-4P 869962-46-9P
 869962-47-0P 869962-48-1P 869962-49-2P
 869962-87-8P 869962-89-0P 869962-90-3P
 869962-91-4P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN
 (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of prodrugs of pyrrolylpyrimidine peptidomimetics as ERK protein kinase inhibitors for treating of cancer and other diseases, conditions, or disorders)

RN 869962-37-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(1S)-1-[(acetoxy)methyl]propyl]amino]-5-
 methyl-4-pyrimidinyl-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.


10798766.trn

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 acid [1-(3-chlorophenyl)-2-hydroxyethyl]-amide was coupled with tert-butoxycarbonyl-N-Me valine to give after deprotection compd. II as hydrochloride salt and tested as pharmacokinetic.

IT 869962-58-3P 869962-88-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of prodrugs of pyrrolylpyrimidine peptidomimetics as ERK protein kinase inhibitors for treating of cancer and other diseases, conditions, or disorders)

RN 869962-58-3 CAPLUS
 CN Butanedioc acid, 1-[(2S)-2-[(4-[5-[(1S)-1-(3-carboxy-1-oxopropoxy)methyl](3-chlorophenyl)methyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-88-9 CAPLUS
 CN L-Valine, N-methyl-, (2S)-2-[(4-[5-[(1S)-1-(3-chlorophenyl)-2-[(2S)-3-methyl-2-(methylethylamino)-1-oxobutoxyethyl]amino]carbonyl]-1H-pyrrol-3-yl)-5-methyl-2-pyrimidinyl]amino]butyl ester, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 869962-38-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(1S)-1-[(acetoxy)methyl]propyl]amino]-5-
 methyl-4-pyrimidinyl-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-39-0 CAPLUS
 CN Carbonic acid, (2S)-2-[(4-[5-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl)-5-methyl-2-pyrimidinyl]amino]butyl ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869962-40-3 CAPLUS
 CN Propanoic acid, 2-methyl-, (2S)-2-(3-chlorophenyl)-2-[(4-[5-methyl-2-[(1S)-1-((2-methyl-1-oxopropoxy)methyl)propyl]amino]-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]aminoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-41-4 CAPLUS
 CN Carbonic acid, (2S)-2-[(4-[5-[(1S)-1-(3-chlorophenyl)-2-[(ethoxycarbonyloxy)ethyl]amino]carbonyl]-1H-pyrrol-3-yl)-5-methyl-2-pyrimidinyl]amino]butyl ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




RN 869962-47-0 CAPLUS
 CN Propanoic acid, 2-dimethyl-, (2S)-2-[(4-[5-[(1S)-1-(3-chlorophenyl)][(2,2-dimethyl-1-oxopropoxy)methyl]amino]carbonyl]-1H-pyrrol-3-yl)-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


NH₂

PAGE 2-A




RN 869962-46-9 CAPLUS
 CN L-Vanine,
 (2S)-2-[(4-[5-[(1S)-2-[(2S)-2-amino-3-methyl-1-oxobutoxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl)-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-48-1 CAPLUS
 CN Propanoic acid, 2-methyl-, (2S)-2-[(4-[5-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl)-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-49-2 CAPLUS
 CN Phosphoric acid, (2S)-2-[(4-[5-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl)-5-methyl-2-pyrimidinyl]amino]butyl diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-87-8 CAPLUS
CN 1H-Pyrole-2-carboxamide,
N-[(1S)-2-(acetoxy)-1-(3-chlorophenyl)ethyl]-4-[2-[(1S)-1-(acetoxy)methyl]propyl]amino]-5-methyl-4-pyrimidinyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



• HCl

RN 869962-89-0 CAPLUS
CN Acetic acid, (2-methoxyethoxy)-, (2S)-2-[(4-[5-[(3S)-3-(3-chlorophenyl)-1,6-dioxa-5,8,11-trioxa-2-azadodec-1-yl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl)amino]butyl ester, monomethanesulfonate (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 2-A

NH₂

• 3 HCl


RN 869962-91-4 CAPLUS
CN 1H-Pyrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-(phosphonoxy)ethyl]-4-[5-methyl-2-[(1S)-1-[(phosphonoxy)methyl]propyl]amino]-4-pyrimidinyl-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CM 1

CRN 869962-61-8
CMF C32 H42 Cl NS O9

Absolute stereochemistry.




CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 869962-90-3 CAPLUS
CN L-Alanine, (2S)-2-[(4-[5-[(2S)-2-amino-1-oxopropoxy]-1-(3-chlorophenyl)ethyl]amino)carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinylamino]butyl ester, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



• Na

IT 869962-42-5P 869962-43-6P 869962-44-7P
869962-45-8P 869962-50-5P 869962-53-8P
869962-56-1P 869962-57-2P 869962-59-4P
869962-60-7P 869962-61-8P 869962-62-9P
869962-63-0P 869962-64-1P 869962-66-3P
869962-67-4P 869962-69-6P 869962-70-9P
869962-72-1P 869962-73-2P 869962-74-3P
869962-76-5P 869962-77-6P 869962-79-8P
869962-80-1P 869962-81-2P 869962-82-3P
869962-83-4P 869962-84-5P 869962-85-6P
869962-86-7P 869962-92-5P 869962-93-6P
869962-94-7P 869962-95-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of prodrugs of pyrrolypyrimidine peptidomimetics as ERK protein kinase inhibitors for treating of cancer and other diseases, conditions, or disorders)

RN 869962-42-5 CAPLUS
CN Carbonic acid, (2S)-2-(3-chlorophenyl)-2-[(4-[5-methyl-2-[(1S)-1-[(phenylmethoxy)carbonyl]oxy]methyl]propyl)amino]-4-pyrimidinyl-1H-pyrrol-2-yl]carbonyl)amino]ethyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 869962-43-6 CAPLUS

CN Phosphoric acid, (2S)-2-(3-chlorophenyl)-2-[[4-[2-[(1S)-1-((diethoxyphosphinyl)oxy)methyl]propyl]amino]-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-44-7 CAPLUS

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 869962-50-5 CAPLUS

CN Carbonic acid, (2S)-2-(3-chlorophenyl)-2-[[4-[2-[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl l-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-53-8 CAPLUS

CN Acetic acid, (2-methoxyethoxy)-, (2S)-2-[[4-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinylamino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-56-1 CAPLUS

CN Acetic acid, [2-(2-methoxyethoxy)ethoxy]-, (2S)-2-[[4-[5-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Carbonic acid, (2S)-2-[[4-[5-[(1S)-1-(3-chlorophenyl)-2-methylethoxy]carbonyl]oxy]ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinylamino]butyl l-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-45-8 CAPLUS

CN Carbonic acid, (2S)-2-[[4-[5-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinylamino]butyl l-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Pyrimidinylamino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-57-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, (2S)-2-[[4-[5-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinylamino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-59-4 CAPLUS

CN L-Valine, 3-methyl-, (2S)-2-[[4-[5-[(1S)-2-[(2S)-2-amino-3,3-dimethyl-1-oxobutoxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinylamino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 869962-60-7 CAPLUS
CN L-Alanine, N-methyl-, (2S)-2-[(4-[5-[(1S)-1-(3-chlorophenyl)-2-((2S)-3-methyl-2-(methylamino)-1-oxobutoxy)ethyl]amino]carbonyl)-1H-pyrrol-3-yl]-5-methyl-2-(pyrimidinyl)amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 869962-61-8 CAPLUS
CN Acetic acid, (2-methoxyethoxy)-, (2S)-2-[(4-[5-((3S)-3-(3-chlorophenyl)-1,6-dioxa-5,8,11-trioxa-2-sazadodec-1-yl)-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl)amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 869962-62-9 CAPLUS
CN L-Alanine, (2S)-2-[(4-[5-[(1S)-2-((2S)-2-amino-1-oxopropoxy)-1-(3-chlorophenyl)ethyl]amino]carbonyl)-1H-pyrrol-3-yl]-5-methyl-2-(pyrimidinyl)amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)

PAGE 2-A

Absolute stereochemistry.

RN 869962-64-1 CAPLUS
CN 4-Morpholinebutanoic acid, γ -oxo-, (2S)-2-(3-chlorophenyl)-2-[(4-[5-methyl-2-[(1S)-1-[(4-(4-morpholinyl)-1,4-dioxobutoxymethyl)propyl]amino)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

PAGE 1-A




PAGE 1-B

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

PAGE 1-A




PAGE 2-A

RN 869962-67-4 CAPLUS

CN L-Leucine, (2S)-2-[(4-[5-[(1S)-2-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]oxy]-1-(3-chlorophenyl)ethyl]amino)carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinylamino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 869962-66-3 CAPLUS
CN L-Isoleucine, (2S)-2-[(4-[5-[(1S)-2-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]oxy]-1-(3-chlorophenyl)ethyl]amino)carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinylamino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

PAGE 1-A



PAGE 2-A

RN 869962-69-6 CAPLUS


CN L-Leucine, (2S)-2-[(4-[5-[(1S)-2-[(2S)-2-amino-4-methyl-1-oxopentyl]oxy]-1-(3-chlorophenyl)ethyl]amino)carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinylamino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

PAGE 1-A




PAGE 2-A

RN 869962-70-9 CAPLUS

CN L-Proline, (2S)-2-[(4-[5-methyl-2-[(1S)-1-[(2S)-2-pyrrolidinyl]carbonyloxy]methyl]propyl]amino)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonylamino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)

PAGE 1-B



RN 869962-72-1 CAPLUS
 CN Alanine, 2-methyl-, (2S)-2-[(4-[5-[(1S)-2-(2-amino-2-methyl-1-oxopropoxy)-1-(3-chlorophenyl)ethyl]amino]carbonyl)-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 869962-73-2 CAPLUS
 CN L-Valine, (2S)-2-[(4-[5-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl)-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-74-3 CAPLUS
 CN L-Valine, (2S)-2-[(4-[2-[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A




L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869962-76-5 CAPLUS
 CN L-Valine, N-methyl-, (2S)-2-[(4-[5-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl)-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-77-6 CAPLUS
 CN L-Valine, N-methyl-, (2S)-2-(3-chlorophenyl)-2-[(4-[2-[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869962-79-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-(phosphonoxyethyl)-4-[2-[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-80-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl)-4-[5-methyl-2-[(1S)-1-((phosphonoxy)methyl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10798766.trn


L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 869962-81-2 CAPLUS
 CN L-Valine, (2S)-2-[(4-[2-((1S)-1-[(acetoxy)methyl]propyl)amino]-5-methyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]amino]-2-(3-chlorophenyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-82-3 CAPLUS
 CN L-Valine, (2S)-2-[(4-[5-((1S)-2-(acetoxy)-1-(3-chlorophenyl)ethyl)amino]carbonyl)-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 869962-84-5 CAPLUS
 CN Alanine, 2-methyl-, (2S)-2-(3-chlorophenyl)-2-[(4-[2-((1S)-1-(hydroxymethyl)propyl)amino]-5-methyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]aminoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-85-6 CAPLUS
 CN Alanine, N,2-dimethyl-, (2S)-2-(3-chlorophenyl)-2-[(4-[2-((1S)-1-(hydroxymethyl)propyl)amino]-5-methyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 869962-83-4 CAPLUS
 CN Alanine, 2-methyl-, (2S)-2-(3-chlorophenyl)-2-[(4-[5-methyl-2-((1S)-1-[(phosphonoxy)methyl]propyl)amino]-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 869962-86-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(1S)-2-(acetoxy)-1-(3-chlorophenyl)ethyl]-4-(5-methyl-2-((1S)-1-[(phosphonoxy)methyl]propyl)amino)-4-pyrimidinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869962-92-5 CAPLUS
 CN Butanedioic acid, 1-[(2S)-2-[(4-[5-((1S)-1-(3-carboxy-1-oxopropoxy)methyl)-3-chlorophenyl)methyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester, disodium salt (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




● 2 Na

RN 869962-93-6 CAPLUS
CN L-Isoleucine, (2S)-2-[(4-[5-[(1S)-2-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]oxy]-1-(3-chlorophenyl)ethyl]amino)carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



PAGE 1-A

NH₂


● 3 HCl

RN 869962-94-7 CAPLUS
CN L-Valine,
(2S)-2-[(4-[5-[(1S)-2-[(2S)-2-amino-3-methyl-1-oxobutoxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A

NH₂


● 3 HCl

RN 869962-95-8 CAPLUS
CN L-Proline, (2S)-2-(3-chlorophenyl)-2-[(4-[5-methyl-2-[(1S)-1-[(2S)-2-pyrorolidinyl]carbonyl]oxy]methyl)propyl]amino)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



● HCl


PAGE 1-B



IT 449732-51-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of prodrugs of pyrrolylpyrimidine peptidomimetics as ERK protein kinase inhibitors for treating of cancer and other diseases, conditions, or disorders)

RN 449732-51-8 CAPLUS
CN 1W-Pyrrole-2-carboxamide,
N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-{2-[(1S)-1-(hydroxymethyl)propyl]amino}-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 869962-96-9P 869962-97-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of prodrugs of pyrrolopyrimidine peptidomimetics as ERK protein kinase inhibitors for treating of cancer and other diseases, conditions, or disorders)

RN 869962-96-9 CAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-, (2S)-2-[(4-[5-
{[(1S)-1-(3-chlorophenyl)-2-[(2S)-2-[(1,1-dimethylethoxy)carbonyl]methyl
amino]-3-methyl-1-oxobutoxyl]ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-
2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

RN 869962-97-0 CAPLUS


CN L-isoleucine, N-[(1,1-dimethylethoxy)carbonyl]-, (2S)-2-[(4-[5-
{[(1S)-1-(3-chlorophenyl)-2-[(2S,3S)-2-[(1,1-dimethylethoxy)carbonyl]amino]-3'-
methyl-1-oxopentyl]oxylethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-
pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 2-A

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TITLE: Preparation of substituted pyrroles, particularly pyrimidinylpyrrolecarboxylic acid esters and amides, as inhibitors of protein kinases such as ERK2, JNK3, Src kinase, Aurora2, and GSK3

INVENTOR(S): Maltsev, Francois; Aronov, Alex; Hale, Michael R.; Moon, Young-choon

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2004083203 | A1 | 20040930 | WO 2004-US7540 | 20040311 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UC, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, CH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004221881 | A1 | 20040930 | AU 2004-221881 | 20040311 |
| CA 2522176 | AA | 20040930 | CA 2004-2522176 | 20040311 |
| US 2004220200 | A1 | 20041104 | US 2004-798766 | 20040311 |
| EP 1606284 | A1 | 20051221 | EP 2004-719833 | 20040311 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| JP 2006520386 | T2 | 20060907 | JP 2006-507111 | 20040311 |
| PRIORITY APPLN. INFO.: | | | US 2003-454405P | P 20030313 |
| | | | WO 2004-US7540 | W 20040311 |

OTHER SOURCE(S): MARPAT 141:314342
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I [A = a pyrrole ring substituted with two R1 groups and OR2 and optionally substituted at the 1-position with R2; O = bond, (un)substituted carbonylamino, sulfonylamino, sulfonyl, aminocarbonylamino, aminocarbonyl, aminosulfonyl, aminosulfonamido, carbonyl, carbonyloxy; R1 = NC, halo, alkoxy or aryloxy, alkylthio or arylthio, (un)substituted amino; R2 = halogen, NC, (un)substituted alkyl; R3 = H, (un)substituted alkyl, aryl; R4 = R6, R6C(:O), R6O2C, R62NC(:O), R6SO2; R6 = alkyl or aryl; Rx = alkyl, halogen,

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 NC, O2N, alkoxy, alkylthio, (un)substituted amino, alkylcarbonyl, alkoxycarbonyl; Ry = (un)substituted alkyl, aryl, amino, alkylthio, alkoxy, NC, O2N, halo, Rz = H, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl; T = bond, alkylidene; U = bond, O, S, alkylimino, (un)substituted alkylidene; X = Tm; Z1, Z2 = N, CRX; m = 0 or 1, particularly pyrimidinylpyrrolecarboxyl derivs. such as II. are prep'd. as inhibitors of protein kinases such as ERK2, JNK3, Src kinase, Aurora2, or GSK3 for the treatment of conditions such as cancer, bone disorders, diabetes, or immune disorders. Pyrrolecarboxylate III is treated with Bredereck's reagent in THF to yield the

dimethylacryloylpolyrrolecarboxylate
 which undergoes cyclocondensation with isopropylguanidine hydrochloride

to yield IV (also an invention compd.); basic hydrolysis of the carboxylate and coupling with (S)-2-amino-2-(3-chlorophenyl)ethanol hydrochloride yields II. Some compds. of the invention inhibit ERK2, JNK3, Src, Aurora2, or GSK3 at concns. of < 5 μ M (and some at concns. of < 1 μ M). (no data). Pharmaceutical compns. contg. I are claimed; in addn., I may be administered with a variety of codrugs such as antiinflammatory, immunomodulatory, or antiviral agents.

IT 766522-50-3P 766522-68-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACR (Reactant or reagent); USES (Uses)

(preparation of substituted pyrroles, particularly

pyrimidinylpyrrolecarboxylic acid esters and amides, as inhibitors of protein kinases such as ERK2, JNK3, Src kinase, Aurora2, and GSK3)

RN 766522-50-3 CAPLUS


CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 766522-68-3 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 766522-03-6P 766522-04-7P 766522-05-8P

766522-06-9P 766522-07-0P 766522-08-1P
 766522-09-2P 766522-10-5P 766522-11-6P
 766522-12-7P 766522-13-8P 766522-14-9P
 766522-15-0P 766522-16-1P 766522-17-2P
 766522-18-3P 766522-19-4P 766522-20-7P
 766522-21-8P 766522-22-9P 766522-23-0P
 766522-24-1P 766522-25-2P 766522-26-3P
 766522-27-4P 766522-28-5P 766522-29-6P
 766522-31-0P 766522-32-1P 766522-33-2P
 766522-34-3P 766522-35-4P 766522-37-6P
 766522-38-7P 766522-39-8P 766522-40-1P
 766522-41-2P 766522-42-3P 766522-43-4P
 766522-44-5P 766522-45-6P 766522-46-7P
 766522-47-8P 766522-48-9P 766522-49-0P
 766522-51-4P 766522-52-5P 766522-53-6P
 766522-54-7P 766522-55-8P 766522-56-9P
 766522-57-0P 766522-58-1P 766522-59-2P
 766522-60-5P 766522-62-7P 766522-69-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrroles, particularly

pyrimidinylpyrrolecarboxylic acid esters and amides, as inhibitors of protein kinases such as ERK2, JNK3, Src kinase, Aurora2, and GSK3)

RN 766522-03-6 CAPLUS


CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 766522-04-7 CAPLUS


CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 766522-05-8 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-, 3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 766522-06-9 CAPLUS


CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-, 3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 766522-07-0 CAPLUS


CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-[2-[(4-nitrophenyl)amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 766522-08-1 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-[2-[(4-phenylmethoxy)phenyl]amino]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 766522-09-2 CAPLUS


CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[(4-aminosulfonyl)phenyl]amino]-4-pyrimidinyl-, 3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-10-5 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-methyl-3-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-11-6 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid,
4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-
5-methyl-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-12-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid,
4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-
5-methyl-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-13-8 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid,
4-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-
5-methyl-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-17-2 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[(4-(aminosulfonyl)phenyl)amino]-4-pyrimidinyl]-3,5-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 766522-18-3 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[(6-chloro-3-pyridinyl)amino]-4-pyrimidinyl]-3,5-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 766522-19-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid,
4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-
3,5-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-14-9 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-methyl-3-phenyl-4-[2-[(3-phenylmethoxy)phenyl]amino]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-15-0 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[(6-chloro-3-pyridinyl)amino]-4-pyrimidinyl]-5-methyl-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-16-1 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-(2-(phenylamino)-4-pyrimidinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-20-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid,
4-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-
3,5-dimethyl-, t-butyl ester (9CI) (CA INDEX NAME)




RN 766522-21-8 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-(2-[(3-phenylmethoxy)phenyl]amino)-4-pyrimidinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 766522-22-9 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-(2-amino-4-pyrimidinyl)-3,5-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 - ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 766522-23-0 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-(2-(methylamino)-4-pyrimidinyl)-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 766522-24-1 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-(2-(ethylamino)-4-pyrimidinyl)-3,5-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 766522-25-2 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-(2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl)-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

L7 - ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 766522-29-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(4-chloro-2-fluorophenyl)amino]-5-hydroxy-4-pyrimidinyl]-N-[(4-fluorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 766522-31-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-(5-cyano-2-[(2,2,2-trifluoroethyl)amino]-4-pyrimidinyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10798766.trn

L7 - ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 766522-26-3 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-(2-(cyclohexylamino)-4-pyrimidinyl)-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-27-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-amino-1-(3-chlorophenyl)ethyl]-4-(2-amino-4-pyrimidinyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 766522-28-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1-(4-fluorophenyl)-2-hydroxyethyl]-4-[5-fluoro-2-[(3,3,3-trifluoro-1-hydroxypropyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

L7 - ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 766522-32-1 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-(5-cyano-2-(phenylamino)-4-pyrimidinyl)-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-33-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 766522-34-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-fluoro-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 766522-35-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-hydroxy-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-48-9 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[(4-(aminosulfonyl)phenyl)amino]-5-(hydroxymethyl)-4-pyrimidinyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-49-0 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-[2-(cyclohexylamino)-5-(hydroxymethyl)-4-pyrimidinyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 766522-51-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3,5-


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
dimethyl-4-[(2-[(1-methylethyl)amino]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 766522-52-5 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-[(2-[(1S)-1-(hydroxymethyl)propyl]amino)-5-(hydroxymethyl)-4-pyrimidinyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 766522-53-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[(2-[(1S)-1-(hydroxymethyl)propyl]amino)-5-(hydroxymethyl)-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 766522-54-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3-(hydroxymethyl)-5-methyl-4-[(2-(methylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 766522-55-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-fluoro-4-pyrimidinyl)-3-[(dimethylamino)methyl]-N-[(4-fluorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 766522-56-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-hydroxy-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]-5-methyl-3-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 766522-57-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-5-(hydroxymethyl)-3-methyl-4-[(2,2,2-trifluoroethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 766522-58-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-(5-fluoro-2-[(2,2,2-trifluoroethyl)amino]-4-pyrimidinyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 766522-59-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-(hydroxymethyl)-2-[(1-methylethyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 766522-60-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-(hydroxymethyl)-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 766522-62-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chloro-4-fluorophenyl)amino]-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 766522-69-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid,
4-[2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2004:56415 CAPLUS
DOCUMENT NUMBER: 141:89104
TITLE: Preparation of 2-substituted 4-heteroarylpyrimidines as GSK3 inhibitors for the treatment of diabetes
INVENTOR(S): Wang, Shudong; Meades, Christopher; Wood, Gavin; Duncan, Kenneth; Zhevela, Daniella; Fischer, Peter
PATENT ASSIGNEE(S): Cyclacel Limited, UK
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|------------------|------------|
| W | WO 2004056368 | A1 | 20040708 | WO 2003-GB5558 | 20031218 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, | | | | |
| TG | CA 2502138 | AA | 20040708 | CA 2003-2502138 | 20031218 |
| AU | 2003292444 | A1 | 20040714 | AU 2003-292444 | 20031218 |
| EP | 1572211 | A1 | 20050914 | EP 2003-768023 | 20031218 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR | 2003016703 | A | 20050108 | BR 2003-16703 | 20031218 |
| CN | 1720049 | A | 20060111 | CN 2003-80104697 | 20031218 |
| JP | 2006515588 | T2 | 20060601 | JP 2004-561646 | 20031218 |
| US | 2005282843 | A1 | 20051222 | US 2005-140136 | 20050526 |
| | | | | GB 2002-29581 | A 20021219 |
| | | | | WO 2003-GB5558 | W 20031218 |


OTHER SOURCE(S): MARPAT 141:89104
GI



L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AB Heteroarylpyrimidines of formula I [X, Y = S, (substituted) N, (substituted) C; R1 = alkyl, aryl, heteroaryl, halo, CF3, CN, (substituted) NH2, alkoxy carbonyl, etc.; R2-R4 = H, alkyl, aryl, heteroaryl, halo, CF3, NO2, OH, alkoxy, acyl, alkoxy carbonyl, (substituted) NH2, SO2-alkyl, etc.] are prepared for use in a medicament for treating diabetes. The compds. of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke. Thus, II was prepared, and had IC50 of 0.005 μ M against GSK3 β .
 IT 467470-28-6P
 RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heteroarylpyrimidines as GSK3 inhibitors)
 RN 467470-28-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:581038 CAPLUS
 DOCUMENT NUMBER: 141:260690
 TITLE: Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl)pyrimidine CDK inhibitors
 AUTHOR(S): Wang, Shudong; Wood, Gavin; Meades, Christopher; Griffiths, Gary; Midgley, Carol; McNaer, Iain; McInnes, Campbell; Anderson, Sian; Jackson, Wayne; Mezna, Mokdad; Yuill, Rhoda; Walkinshaw, Malcolm; Fischer, Peter M.
 CORPORATE SOURCE: Cyclacel Limited, James Lindsay Place, Dundee, DD1 5JJ, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(16), 4237-4240
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:260690
 GI



AB A series of 2-anilino-4-(1H-pyrrol-3-yl)pyrimidines were prepared and evaluated for their ability to inhibit cyclin-dependent kinases (CDKs). A number of analogs, e.g., I, were found to be potent CDK2 and CDK4 inhibitors and to exhibit anti-proliferative activity against human tumor cell lines. Structure-activity relationships and biochemical characterization are presented.
 IT 467470-28-6P
 RU: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, kinase inhibition, and anti-proliferative activity of anilinodimethylpyrrolylpyrimidines via cyclocondensation of phenylguanidines with dimethylpyrrolyl-enaminones)
 RN 467470-28-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-3,5-

L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dimethyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:975281 CAPLUS
 DOCUMENT NUMBER: 139:364952
 TITLE: Preparation of pyrrole derivatives as inhibitors of ERK2
 INVENTOR(S): Hale, Michael R.; Maltais, Francois; Tang, Qing; Straub, Judith; Aronov, Alexander
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 2003091246 | A1 | 20031106 | WO 2003-US13186 | 20030425 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003237121 | A1 | 20031110 | AU 2003-237121 | 20030425 |
| US 2004029857 | A1 | 20040212 | US 2003-424280 | 20030425 |
| EP 1506189 | A1 | 20050216 | EP 2003-736503 | 20030425 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| US 2005234059 | A1 | 20051020 | US 2005-77188 | 20050310 |
| PRIORITY APPN. INFO.: | | | US 2002-376259P | P 20020426 |
| | | | US 2002-403853P | P 20020814 |
| | | | US 2003-424280 | A3 20030425 |
| | | | WO 2003-US13186 | W 20030425 |

OTHER SOURCE(S): MARPAT 139:364952
 GI



L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Pyrroles I [Al, A2 = N, (un)substituted CH; T = bond, (un)substituted CH2, CO, COCO, CONH, CONHNH, CO2, O2C, NHCO, O, NHCONH, O2CNH, NHNN, NHCO2, S, S(O), SO2, NH, SO2NH, NHSO2, NHSO2NH; X = CO, (un)substituted CONH, NHCO, NHSO2, SO2NH, S(O), SO2; R1 = H, CN, halogen, (un)substituted NH2, OH, aliphatic, cycloaliph., aromatic, heterocyclic, heteroarom.; R2 = (un)substituted alkyl, NH2, OHNH2, NHOH, OH, CO2H, SH, NHCONH2, CONH2, SO2H, NHSO2H, SO2NH2, acyl, aliphatic, cycloaliph., aromatic, heterocyclic, heteroarom.; R3 = aliphatic, cycloaliph., aromatic, heterocyclic, especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases for treating diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease. Thus, 2-trichloroacetylpyrrole was converted to the


4-(3-methoxypropionyl) derivative and then to the amide with (S)-phenylglycinol. The amide was treated with Brederick's reagent and cyclized with benzamidine to give I [Al = N, A2 = CH, T = bond, R1 = Me, R3 = Ph, R4-R6 = H, XR2 = (S)-CONHCPhCH2OH, II]. II had Ki < 0.1 nM for inhibition of ERK2.

IT 620615-80-7P 620615-81-8P 620615-82-9P
620615-83-0P 620615-84-1P 620615-85-2P
620615-86-3P 620615-87-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrole derivs. as inhibitors of ERK2)

RN 620615-80-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]-4-[5-methyl-2-(trimethylhydrazino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 620615-84-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-[(2-hydroxyethoxy)methylamino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 620615-85-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-[(2-hydroxyethoxy)methylamino]-4-pyrimidinyl]-1-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[5-methyl-2-(trimethylhydrazino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 620615-88-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-chloro-2-(trimethylhydrazino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 620615-83-0 CAPLUS
CN Acetic acid, 2-[5-chloro-4-[5-[[((1S)-2-hydroxy-1-phenylethyl)amino]carbonyl]-1H-pyrol-3-yl]-2-pyrimidinyl]-1,2-dimethylhydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 620615-86-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-[(2-hydroxyethoxy)methylamino]-4-pyrimidinyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 620615-87-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3-methyl-4-[2-(trimethylhydrazino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:849586 CAPLUS
 DOCUMENT NUMBER: 137:370099
 TITLE: Preparation of 3-aminopyrazolo[3,4-c]pyridazines as inhibitors of glycogen synthase kinase-3 and crystal structures of gsk-3 β protein and protein complexes
 INVENTOR(S): Ter Haar, Ernst; Swenson, Lovorka; Green, Jeremy; Arnost, Michael J.
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 778 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 200208078 | A2 | 20021107 | WO 2002-US13511 | 20020429 |
| WO 200208078 | A3 | 20040506 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2444882 | RA | 20021107 | CA 2002-2444882 | 20020429 |
| AU 2002259071 | A1 | 20021111 | AU 2002-259071 | 20020429 |
| US 2003125332 | A1 | 20030703 | US 2002-135255 | 20020429 |
| EP 1435957 | A2 | 20040714 | EP 2002-729056 | 20020429 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2005504731 | T2 | 20050217 | JP 2002-585380 | 20020429 |
| PRIORITY APPLN. INFO.: | | | US 2001-287366P | P 20010430 |
| | | | US 2001-297094P | P 20010608 |
| | | | US 2002-361899P | P 20020227 |
| | | | WO 2002-US13511 | W 20020429 |

OTHER SOURCE(S): MARPAT 137:370099
 GI

L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. [I]; R1 = H, RCO, RO₂C, (substituted) aliphaticl, carbocyclicl, heteroaryl, etc.; R2, R3 = H, (substituted) aliphaticl, carbocyclicl, heteroaryl, aryl, aralkyl, heteroaryl, heteroaralkyl, NR2, NRCOR, SR, OR, CF3 halo, NO2, cyano, etc.; R = H, (substituted) aliphaticl, carbocyclicl, heteroaryl, aryl, aralkyl, heteroaryl, heteroaralkyl), were prepared. Thus, 3-chloro-4-cyano-5,6-diphenylpyridazine was refluxed with NH₂H in EtOH to give 3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine. The latter inhibited gsk-3 with Ki₅₀ 0.1 μM.

IT 474381-76-5
 RL: PTP (Properties); SPN (Synthetic preparation); PREP (Preparation) (crystal structure determination; preparation of pyrazolopyridazines as inhibitors of gsk-3 and crystal structures of gsk-3 β protein and protein complexes)

RN 474381-76-5 CAPLUS
 CN Kinase (phosphorylating), glycogen synthetase (human isoenzyme 3B), compd. with N-(2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)-4-pyrimidinyl-1H-pyrrole-2-carboxamide (1:1) (9C1) (CA INDEX NAME)

CM 1
 CRN 474381-75-4
 CMF C24 H23 N5 O2




CM 2
 CRN 474231-10-2
 CMF Unspecified
 CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:777930 CAPLUS
 DOCUMENT NUMBER: 137:294968
 TITLE: Preparation of 4-(1H-pyрrolyl)pyrimidin-2-ylamines as inhibitors of cyclin dependent kinases for treating cancer
 INVENTOR(S): Fischer, Peter Martin; Wang, Shudong; Wood, Gavin
 PATENT ASSIGNEE(S): Cyclacel Limited, UK
 SOURCE: PCT Int. Appl., 73 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2002079193 | A1 | 20021010 | WO 2002-GB1445 | 20020326 |
| WO 2002079193 | C1 | 20050317 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2440228 | RA | 20021010 | CA 2002-2440228 | 20020326 |
| EP 1373253 | A1 | 20040102 | EP 2002-718319 | 20020326 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2002008447 | A | 20040302 | BR 2002-8447 | 20020326 |
| CN 1503794 | A | 20040609 | CN 2002-807553 | 20020326 |
| JP 2004538260 | T2 | 20041224 | JP 2002-577818 | 20020326 |
| NZ 528347 | A | 20050729 | NZ 2002-528347 | 20020326 |
| GB 2375534 | A1 | 20021120 | GB 2002-7229 | 20020327 |
| GB 2375534 | B2 | 20030924 | | |
| US 2004132746 | A1 | 20040708 | US 2003-671747 | 20030924 |
| PRIORITY APPLN. INFO.: | | | GB 2001-7901 | A 20010329 |
| | | | WO 2002-GB1445 | W 20020326 |

OTHER SOURCE(S): MARPAT 137:294968
 GI



AB The title compds. [I]: one of X1 and X2 = NR10 and the other of X1 and X2

CR9; Z = NH; NHCO, NHSO₂, etc.; RI-R3, R9, R10 = H, alkyl, aryl, etc.; R4-R8 = H, alkyl, halo, etc.; with the proviso), useful as inhibitors of cyclin-dependent kinases (CDKs) and hence useful in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like, were prepared. Thus, heating 3-dimethylamino-1-(2,4-dimethyl-1H-pyrrol-3-yl)propanoic (preparation given) with 4-fluorophenyl guanidine nitrate in the presence of NaOH in 2-methoxyethanol at 100-120°C under N₂ for 6 h afforded 62% II which showed IC₅₀ of 1.0±0.7 μM against CDK2/cyclin E.


IT 467470-28-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Uses) (Drug candidate; preparation of 4-(1H-pyrrolyl)pyrimidin-2-ylamines as inhibitors of cyclin dependent kinases for treating cancer)

RN 467470-28-6 CAPLUS


CN 1H-Pyrrole-2-carboxamide, 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:637673 CAPLUS
DOCUMENT NUMBER: 137:185518
TITLE: Pyrimidine derivatives as ERK2 inhibitors
INVENTOR(S): Cao, Jingrong; Green, Jeremy; Hale, Michael; Maltais, Francois; Straub, Judy; Tang, Qing; Aronov, Alex
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 188 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--|-----------------|-----------------|----------|
| WO 2002064586 | A2 | 20020822 | WO 2002-US3791 | 20020208 |
| WO 2002064586 | A3 | 20030206 | | |
| W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MU, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | |
| RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, T2, UG, 2M, 2W, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | AA | 20020822 | CA 2002-2437767 | 20020208 |
| US 20030092714 | A1 | 20030515 | US 2002-71699 | 20020208 |
| US 6743791 | B2 | 20040601 | | |
| EP 1363906 | A2 | 20031126 | EP 2002-724922 | 20020208 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | BR 2002-7114 | | | |
| BR 2002007114 | A | 20040225 | BR 2002-7114 | 20020208 |
| HU 200304052 | A2 | 20040428 | HU 2003-4052 | 20020208 |
| CN 1494541 | A | 20040505 | CN 2002-805766 | 20020208 |
| JP 20042520402 | T2 | 20040708 | JP 2002-564517 | 20020208 |
| HZ 527251 | A | 20060929 | HZ 2002-527251 | 20020208 |
| ZA 2003005799 | A | 20040728 | ZA 2003-5799 | 20030728 |
| NO 2003003491 | A | 20031008 | NO 2003-3491 | 20030806 |
| US 2004229875 | A1 | 20041118 | US 2004-770814 | 20040203 |
| AU 2006202623 | A1 | 20060713 | AU 2006-202623 | 20060620 |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 2001-267818P | P | 20010209 |
| | | US 2001-320768P | P | 20011012 |
| | | AU 2002-255521 | A3 | 20020208 |
| OTHER SOURCE(S): MARPAT 137:185518 | | US 2002-71699 | A3 | 20020208 |
| GI | | WO 2002-US3791 | W | 20020208 |



AB Pyrimidines I [Z1, Z2 = N, CH; X = 5-membered heterocarbo. ring to which

QR2 is attached in the 3-position relative to the pyrimidine ring attachment; U = linker group; U = NR4, NR4CO, NR4CONR4, NR4CO2, O, CONR4, CO, CO2, O2C, NR4SO2, SO2NR4, NR4SO2NR4, SO2; m, n = 0, 1; R1 = CN, halogen, NR42, (un)substituted OH; R2 = (un)substituted alkyl, NH2; R3 = H,

(un)substituted alkyl, CN; R4 = H, (un)substituted alkyl; NR42 = heterocyclic] were prepared for use as inhibitors of ERK2 and for

treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease. Thus, the pyrimidine II was obtained by cyclizing the 3-dimethylamino-2-methylacryloylpyrrole fragment

with (S)-HOCH2CHPhNNHC(:NH)NH2. II had ki <0.1 μM for inhibition of ERK2 in vitro.

IT 449731-36-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Preparation of pyrimidine derivs. as ERK2 inhibitors)

RN 449731-36-6 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[2-[(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 449730-22-7P 449730-23-8P 449730-24-9P
 449730-25-0P 449730-26-1P 449730-27-2P
 449730-28-3P 449730-29-4P 449730-30-7P
 449730-31-8P 449730-32-9P 449730-33-0P
 449730-34-1P 449730-35-2P 449730-36-3P
 449730-37-4P 449730-38-5P 449730-39-6P
 449730-40-9P 449730-41-0P 449730-42-1P
 449730-43-2P 449730-44-3P 449730-45-4P
 449730-46-5P 449730-47-6P 449730-48-7P
 449730-49-8P 449730-50-1P 449730-51-2P
 449730-52-3P 449730-53-4P 449730-54-5P
 449730-55-6P 449730-56-7P 449730-57-8P
 449730-59-0P 449730-60-3P 449730-61-4P
 449730-62-5P 449730-63-6P 449730-64-7P
 449730-65-8P 449730-66-9P 449730-67-0P
 449730-68-1P 449730-69-2P 449730-70-5P
 449730-71-6P 449730-72-7P 449730-73-8P
 449730-74-9P 449730-75-0P 449730-76-1P
 449730-77-2P 449730-78-3P 449730-79-4P
 449730-80-7P 449730-81-8P 449730-82-9P
 449730-83-0P 449730-84-1P 449730-85-2P
 449730-86-3P 449730-87-4P 449730-88-5P
 449730-89-6P 449730-90-9P 449730-91-0P
 449731-00-4P 449731-19-5P 449731-20-8P
 449731-21-9P 449731-22-0P 449731-23-1P
 449731-24-2P 449731-26-4P 449731-30-0P
 449731-31-1P 449731-33-3P 449731-35-5P
 449731-39-9P 449731-40-2P 449731-41-3P
 449731-42-4P 449731-43-5P 449731-44-6P
 449731-50-4P 449731-51-5P 449731-52-6P
 449731-53-7P 449731-54-8P 449731-56-0P
 449731-57-1P 449731-58-2P 449731-59-3P
 449731-60-6P 449731-62-8P 449731-63-9P
 449731-64-0P 449731-65-1P 449731-66-2P
 449731-67-3P 449731-68-4P 449731-69-5P
 449731-70-8P 449731-71-9P 449731-72-0P
 449731-73-1P 449731-74-2P 449731-75-3P
 449731-76-4P 449731-77-5P 449731-78-6P
 449731-79-7P 449731-80-0P 449731-81-1P
 449731-83-3P 449731-85-5P 449731-86-6P
 449731-87-7P 449731-88-8P 449731-89-9P
 449731-90-2P 449731-91-3P 449731-92-4P
 449731-93-5P 449731-94-6P 449731-95-7P
 449731-96-8P 449731-97-9P 449731-98-0P
 449732-01-8P 449732-05-2P 449732-06-3P
 449732-07-4P 449732-08-5P 449732-10-9P
 449732-12-1P 449732-13-2P 449732-14-3P
 449732-15-4P 449732-16-5P 449732-17-6P
 449732-18-7P 449732-19-8P 449732-20-1P
 449732-21-2P 449732-22-3P 449732-23-4P
 449732-24-5P 449732-25-6P 449732-26-7P
 449732-27-8P 449732-28-9P 449732-29-0P
 449732-30-3P 449732-31-4P 449732-32-5P
 449732-33-6P 449732-34-7P 449732-35-8P
 449732-36-9P 449732-37-0P 449732-38-1P


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 449732-39-2P 449732-40-5P 449732-41-6P
 449732-42-7P 449732-43-8P 449732-44-9P
 449732-45-0P 449732-46-1P 449732-47-2P
 449732-48-3P 449732-49-4P 449732-50-7P
 449732-51-8P 449732-52-9P 449732-53-0P
 449732-54-1P 449732-55-2P 449732-56-3P
 449732-57-4P 449733-07-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of pyrimidine derivs. as ERK2 inhibitors)

RN 449730-22-7 CAPLUS
 CN Pyrrolidine,
 1-[(4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-23-8 CAPLUS
 CN Pyrrolidine,
 1-[(4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-24-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-phenyl-4-pyrimidinyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-25-0 CAPLUS
 CN Morpholine, 4-[(4-(2-amino-5-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-26-1 CAPLUS
 CN 1,4'-Bipiperidine, 1'-(4-(2-amino-5-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-27-2 CAPLUS
 CN 3-Piperidinol, 1-[(4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-28-3 CAPLUS
 CN 1,4'-Bipiperidine,
 1'-(4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-29-4 CAPLUS
 CN 1,4'-Bipiperidine, 1'-(4-(2-amino-5-(3-methylphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-30-7 CAPLUS
 CN 1,4'-Bipiperidine, 1'-(4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 449730-31-8 CAPLUS
CN 4-Piperidinol,
1-[(4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-32-9 CAPLUS
CN Piperazine, 1-[(4-[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 449730-33-0 CAPLUS
CN Piperazine, 1-[(4-[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449730-37-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-N-(2-(3-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 449730-38-5 CAPLUS
CN Morpholine, 4-[(4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-39-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-N-(2-(3-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-34-1 CAPLUS
CN Pyridine,
1-[(4-[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-
4-(4-fluorophenyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-35-2 CAPLUS
CN Piperazine, 1-[(4-[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 449730-36-3 CAPLUS
CN Morpholine, 4-[(4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 449730-40-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-N-(2-(3-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 449730-41-0 CAPLUS
CN Piperazine, 1-[(4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 449730-42-1 CAPLUS
CN Piperazine, 1-[(4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 449730-43-2 CAPLUS
CN Pyridine, 1-[(4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-(4-fluorophenyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-44-3 CAPLUS
CN Isoquinoline, 2-[(4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-45-4 CAPLUS
CN Piperazine, 1-[(4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 449730-46-5 CAPLUS
CN Morpholine, 4-[(4-[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-50-1 CAPLUS
CN Piperazine, 1-[(4-[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 449730-51-2 CAPLUS
CN 3-Piperidinemethanol, 1-[(4-[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-52-3 CAPLUS
CN Isoquinoline, 2-[(4-[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-47-6 CAPLUS
CN 4-Piperidinol, 1-[(4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-48-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-(4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl- (9CI) (CA INDEX NAME)




RN 449730-49-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-phenyl-4-pyrimidinyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 449730-53-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449730-54-5 CAPLUS
CN Pyridine, 1-[(4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-(4-fluorophenyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-55-6 CAPLUS
CN Isoquinoline, 2-[(4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-56-7 CAPLUS
 CN 1H-Pyrole-2-carboxamide, 4-(2-amino-5-(3-methoxyphenyl)-4-pyrimidinyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 449730-57-8 CAPLUS
 CN Piperazine, 1-[4-(2-amino-5-(3-methoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 449730-59-0 CAPLUS
 CN Isoquinoline, 2-[(4-(2-amino-5-(3-methoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-63-6 CAPLUS
 CN 3-Piperidineethanol, 1-[(4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-64-7 CAPLUS
 CN Piperazine, 1-[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 449730-65-8 CAPLUS
 CN Piperazine, 1-[4-(2-amino-5-(3-methoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 449730-60-3 CAPLUS
 CN 1H-Pyrole-2-carboxamide, 4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449730-61-4 CAPLUS
 CN 1H-1,4-Diazepine, 1-[(4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 449730-62-5 CAPLUS
 CN 1H-Pyrole-2-carboxamide, 4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449730-66-9 CAPLUS
 CN 3-Piperidinol, 1-[(4-(2-amino-5-(3-methoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-67-0 CAPLUS
 CN Piperazine, 1-[(4-(2-amino-5-(3-methoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 449730-68-1 CAPLUS
 CN Pyridine, 1-[(4-(2-amino-5-(3-methoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl)carbonyl]-4-(4-fluorophenyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-69-2 CAPLUS
CN Piperazine, 1-[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 449730-70-5 CAPLUS
CN Piperazine, 1-[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 449730-71-6 CAPLUS
CN 1H-1,4-Diazepine, 1-[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-72-7 CAPLUS
CN Piperazine, 1-acetyl-4-[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 449730-73-8 CAPLUS
CN Isoquinoline, 2-[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-74-9 CAPLUS
CN 3-Piperidinol, 1-[4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-75-0 CAPLUS
CN 1H-1,4-Diazepine, 1-[4-(2-amino-5-(3-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 449730-76-1 CAPLUS
CN Piperazine, 1-acetyl-4-[4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 449730-77-2 CAPLUS
CN 1H-1,4-Diazepine, 1-[4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449730-78-3 CAPLUS
CN 3-Piperidinol, 1-[4-(2-amino-5-(3-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)



RN 449730-79-4 CAPLUS
CN 3-Piperidineethanol, 1-[4-(2-amino-5-(3-methylphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 449730-80-7 CAPLUS
CN 3-Piperidineethanol, 1-[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 449730-81-8 CAPLUS
 CN 1H-Pyrrrole-2-carboxamide, 4-[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 449730-82-9 CAPLUS
 CN Piperazine, 1-[(4-[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-83-0 CAPLUS
 CN 4-Piperidinol, 1-[(4-[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-87-4 CAPLUS
 CN 1-Piperazineethanol, 4-[(4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-98-5 CAPLUS
 CN Piperazine, 1-acetyl-4-[(4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-99-6 CAPLUS
 CN Piperazine, 1-[(4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 449730-94-1 CAPLUS
 CN 4-Piperidinol, 1-[(4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-85-2 CAPLUS
 CN 4-Piperidinol, 1-[(4-[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-86-3 CAPLUS
 CN Piperazine, 1-[(4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 449730-90-9 CAPLUS
 CN 1-Piperazineethanol, 4-[(4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-91-0 CAPLUS
 CN Morpholine, 4-[(4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449731-00-4 CAPLUS
 CN 1H-Pyrrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(2S)-tetrahydro-2-furanyl]methyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 449731-19-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-(2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl)-
N-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)




RN 449731-20-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-(2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl)-
N-[2-(dimethylamino)-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 449731-21-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-(2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl)-
N-[(4-(methylsulfonyl)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-22-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4-(5-(3,5-dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 449731-23-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(5-(3,5-dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl)-N-[2-(4-morpholinyl)-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 449731-24-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-(3-fluoro-5-


Absolute stereochemistry.




RN 449731-26-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 449731-30-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(5-methyl-2-(phenylamino)-4-pyrimidinyl)-N-propyl- (9CI) (CA INDEX NAME)



RN 449731-31-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-(5-methyl-2-(phenylamino)-4-pyrimidinyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 449731-33-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-cyclopropyl-4-(2-(ethylamino)-5-methyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 449731-35-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-((1S)-2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-39-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-(2-aminoethyl)-4-(5-methyl-2-(phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 449731-30-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 449731-41-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 449731-42-4 CAPLUS
 CN Piperazine, 1-acetyl-4-[(4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 449731-43-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 449731-52-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-(5-methyl-2-(methylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 449731-53-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-(5-methyl-2-(phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 449731-54-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-44-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-ethyl-4-pyrimidinyl)-N-[2-(6-methoxy-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 449731-50-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-(diethylamino)ethyl)amino]-5-methyl-4-pyrimidinyl]-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-51-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-[(2-(1-piperidinyl)-4-quinazolinyl)amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 449731-56-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-hydroxyphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-57-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(1,3-benzodioxol-5-ylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 449731-58-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(4-(aminosulfonyl)phenyl)amino]-5-methyl-4-
 pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-59-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-
 [(3-(phenylmethoxy)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 449731-60-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(trans-4-hydroxycyclohexyl)amino]-5-methyl-
 4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-62-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[5-cyclopropyl-2-(phenylamino)-4-pyrimidinyl]-
 N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 449731-63-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(1-(3-fluoro-4-methylphenyl)-2-hydroxyethyl)-4-
 [5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 449731-64-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-(2-hydroxy-1-(3-(trifluoromethyl)phenyl)ethyl)-
 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 449731-65-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(1-(3-fluoro-4-methylphenyl)-2-hydroxyethyl)-4-
 [2-(3-(fluorophenyl)amino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 449731-66-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-((3-fluorophenyl)amino)-5-methyl-4-
 pyrimidinyl]-N-[2-hydroxy-1-(3-(trifluoromethyl)phenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449731-67-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-
 [(3-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-68-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 [(phenylmethyl)amino]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-69-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3,4-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-70-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(4-(phenylmethoxy)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 449731-73-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(1S)-2-hydroxy-1-phenylethyl]amino]-5-methyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-74-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(2-methoxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-75-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(4-(trifluoromethoxy)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-71-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-72-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2,2,2-trifluoroethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-76-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2-methylpropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-77-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(cyclopropylmethyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 449731-78-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-(methoxymethyl)-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-79-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(methoxymethyl)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-80-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 449731-85-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-, *rel-* (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 449731-86-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(2-hydroxy-2-phenylethyl)-] (9CI) (CA INDEX NAME)



RN 449731-87-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-88-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10798766.trn

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-81-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-(propylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-83-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-((1R)-2-hydroxy-1-phenylethyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-89-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1R)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-90-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-91-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(1-hydroxymethyl)cyclopropyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-92-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-hydroxyethyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-93-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(1R)-2-hydroxy-1-methylethyl]amino]-5-methyl-4-pyrimidinyl-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-94-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(2R)-2-hydroxypropyl]amino]-5-methyl-4-pyrimidinyl- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-97-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(2-amino-4-pyrimidinyl)-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 449731-98-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-2-hydroxy-1-methyl-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-01-8 CAPLUS
CN Benzenoacetic acid, α -[[[4-(2-(ethylamino)-5-methyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]amino]-, methyl ester, (uS)- (9CI) (CA INDEX NAME)

10798766.trn


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 449731-95-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(2S)-2-hydroxypropyl]amino]-5-methyl-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-96-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-hydroxycyclohexyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 449732-05-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(2-hydroxy-1-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 449732-06-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-(ethylamino)-5-(hydroxymethyl)-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-07-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-(ethylamino)-5-methyl-4-pyrimidinyl)-N-[(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-08-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[1-(3-fluorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 449732-10-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[1-(2-fluorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)



RN 449732-12-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-cyclopropyl-1-


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (hydroxymethyl)ethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-13-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,3-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-14-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethoxyamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449732-15-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-16-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(2-oxo-1-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449732-17-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-18-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-19-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-20-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(1S)-2-hydroxy-1-phenylethyl]amino]-5-methyl-4-pyrimidinyl-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-21-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-22-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-(cyclopropylamino)-5-methyl-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-(2-methoxyphenyl)ethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-23-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-(2-(cyclopropylamino)-5-methyl-4-pyrimidinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-24-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-25-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-(2-(methoxymino)-5-methyl-4-pyrimidinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449732-26-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-((1-methylethoxy)amino)-4-pyrimidinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-27-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-((1-dimethylamino)phenyl)amino)-5-methyl-4-pyrimidinyl-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 449732-28-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-{(2-
 [(2-hydroxyphenyl)amino]-5-methyl-4-pyrimidinyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-29-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-{(2-
 [(1S)-2-hydroxy-1-phenylethyl]amino}carbonyl]amino]-5-methyl-4-
 pyrimidinyl}- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-30-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-{[2-[(2,3-dimethylphenyl)amino]-5-methyl-4-


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-31-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-
 pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-32-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(acetylamino)-5-methyl-4-pyrimidinyl]-N-
 [(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-33-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-{[5-methyl-2-
 [(2-methylphenyl)amino]-4-pyrimidinyl}- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-34-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-{[5-methyl-2-
 (3-pyridinylamino)-4-pyrimidinyl}- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449732-35-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-{[5-methyl-2-
 [(2S)-tetrahydro-2-furanyl]methyl]amino}-4-pyrimidinyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-36-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-{[5-methyl-2-
 [(2R)-tetrahydro-2-furanyl]methyl]amino}-4-pyrimidinyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-37-0 CAPLUS
CN Hydrazinecarboxylic acid, 2-[4-[(5-[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-38-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-(5-methyl-2-(3-pyridinylmethyl)amino)-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-39-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(cyclopropylmethoxy)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-40-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-(2-(3-isoxazolylamino)-5-methyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 449732-41-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(1S)-2-hydroxy-1-methylethyl]amino]-5-methyl-4-pyrimidinyl-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-42-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[5-methyl-2-((2-methylphenyl)amino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-43-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-(5-methyl-2-((2-methylphenyl)amino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-44-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-hydroxyethoxy)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-45-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-(2,2-dimethylhydrazino)-5-methyl-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-46-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-(5-methyl-2-[(2-(trifluoromethyl)phenyl]amino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-47-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-(5-methyl-2-(4-morpholinylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-48-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-(5-methyl-2-(5-methyl-3-isoxazolyl)amino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 449732-49-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-[(1S)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]amino)-5-methyl-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-50-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-fluorophenyl)-2-hydroxyethyl]-4-(5-methyl-2-(phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-51-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-(2-[(1S)-1-(hydroxymethyl)propyl]amino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-52-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-(2-[(2-hydroxy-1-(hydroxymethyl)ethyl]amino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 449732-53-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[{(1S)-2-hydroxy-1-(3-methylphenyl)ethyl}-4-{[(1S)-1-(hydroxymethyl)propyl]amino}-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-54-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-{[2-{(2-hydroxy-1-(hydroxymethyl)ethyl}amino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 449732-57-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyanoamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449733-07-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-N-methyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




IT 338403-73-9P 449730-58-9P 449730-92-1P
 449730-83-2P 449730-94-1P 449730-95-4P
 449730-96-5P 449730-97-6P 449730-99-7P
 449730-89-8P 449731-01-5P 449731-02-6P
 449731-03-7P 449731-04-8P 449731-05-9P
 449731-06-0P 449731-07-1P 449731-08-2P
 449731-09-3P 449731-10-6P 449731-11-7P
 449731-12-8P 449731-13-9P 449731-14-0P
 449731-15-1P 449731-16-2P 449731-17-3P

10798766.trn


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 449732-55-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[{[(1S)-1-(hydroxymethyl)propyl]amino}-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-56-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-(5-methyl-2-[(2-methylcyclopropyl)amino]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)

449731-18-4P 449731-25-3P 449731-27-5P
 449731-28-6P 449731-29-7P 449731-32-2P
 449731-34-4P 449731-37-7P 449731-38-8P
 449731-45-7P 449731-46-8P 449731-47-9P
 449731-48-0P 449731-49-1P 449731-55-9P
 449731-61-7P 449731-82-2P 449731-84-4P
 449732-03-0P 449732-04-1P
 RII: SPW (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (prepn. of pyrimidine derivs. as ERK2 inhibitors)


RN 338403-73-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-(2-amino-5-phenyl-4-pyrimidinyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 449730-58-9 CAPLUS
 CN 1H-1,4-Diazepine, 1-[(4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl)carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 449730-92-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 449730-93-2 CAPLUS

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449730-94-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449730-95-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449730-96-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-01-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(1R)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-02-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-03-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-4-(2,5-diamino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-97-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449730-98-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449730-99-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(1R)-tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-04-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-(methylamino)-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-05-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[5-(acetylamino)-2-amino-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-06-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-[(methylamino)carbonyl]amino]-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-07-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-hydroxy-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-08-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-[(methylamino)methyl]-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-09-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(hydroxymethyl)-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-13-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(methylsulfonyl)-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-14-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(hydroxymethyl)-4-pyrimidinyl]-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-15-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclohexylamino)-5-methyl-4-pyrimidinyl]-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-10-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-4-[2-(cyclohexylamino)-5-[(methylamino)carbonyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 449731-11-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(acetylamino)-5-[(methylamino)carbonyl]amino]-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-12-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-4-[5-hydroxy-



RN 449731-16-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl]-N-[(4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-17-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-(3,5-dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl]-N-[(3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-18-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl]-N-[(1R)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 449731-25-3 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-propyl-4-pyrimidinyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449731-27-5 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(methylamino)-4-pyrimidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 449731-28-6 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[2-(methylamino)-4-pyrimidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

(trifluoromethyl)phenylmethyl]- (9CI) (CA INDEX NAME)




RN 449731-37-7 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-4-pyrimidinyl]-N-(4-methylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 449731-38-8 CAPLUS


CN 1H-Pyrrole-2-carboxamide, 4-[5-ethyl-2-(phenylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 449731-45-7 CAPLUS


CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-29-7 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-(dimethylamino)ethyl]-4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-32-2 CAPLUS


CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 449731-34-4 CAPLUS


CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-4-pyrimidinyl]-N-[2-(

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-46-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-(1-methyl-3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449731-47-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-(1H-benzimidazol-2-ylmethyl)-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 449731-48-0 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[((S)-1-hydroxymethyl)-3-methylbutyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 449731-49-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(1H-imidazol-4-ylmethyl)ethyl]-4-[5-methyl-2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-55-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-(2-[(3-methoxyphenyl)amino]-5-methyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 449731-99-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-(2-hydroxy-2-phenylethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 449732-00-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(2S)-2-hydroxy-2-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-02-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)


RN 449731-61-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[5-cyclohexyl-2-(phenylamino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-82-Z CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[5-(hydroxymethyl)-2-(phenylamino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-84-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 449732-03-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-04-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-(methoxymethyl)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Page 51

| | | |
|--|------------------|---------------|
| => log h | | |
| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
| FULL ESTIMATED COST | 54.22 | 222.25 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -6.75 | -6.75 |

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:49:26 ON 14 DEC 2006

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLORED OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox